Business Description
NGeneBio, founded in 2015 and based in Seoul, South Korea, develops genetic testing products and software used to diagnose and monitor a range of serious conditions, including several cancers, tuberculosis, and COVID-19. Its product line includes laboratory reagent kits for breast, ovarian, and blood cancers, as well as tools for identifying genetic markers in solid tumors and human leukocyte antigens. The company also offers software platforms that help clinicians and researchers interpret the complex data produced by next-generation sequencing tests.
